3Takamatsu Y,Yuki S,Watanabe T.Studies on the concentration of 3-methl-1-lphenyl-2-pyrazoln-5-one(MCL-186) in MCA occlusion and reperfuslon model of rats[J].J PN Phamacol Ther,1997,25(Suppl):1785-1791.
4Takabatake Y,Uno E.The clinical effect of combination therapy with edaravone and sodium ozagral for acute cerebral infarction[J].No To Shinkei,2003,55(7):589.
5Lewen A,Matz P,Chan PH.Free radical pathways in CNS iniury[J].Neurotrauma,2000,17:871-890.
6Edaravone Acute Infarction Study Group.Effect of novel free radical cavenger,edaravone (MCL-186),on acute vrain infarction.Randomized,placebocontrolled,double-blind study atmulticenters[J].Cerbrobasc Dis,2003,15(1):221-229.
二级参考文献6
1Jain KK. Neuroprotection in cerebrovascular disease. Expert Opin Investig Drugs, 2000,9:695
2Tanaka M. Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nippon Yakurigaku Zasshi, 2002, 119:301
3Edaravone Acute Infarction Study Group. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis, 2003, 15:222
4Tabrizchi R. Edaravone Mitsubishi-Tokyo. Curr Opin Investig Drugs, 2000,1:347
5Jin YJ, Mima T, Raicu V, et al. Combined argatroban and edaravone caused additive neuroprotection against 15 min of forebrain ischemia in gerbils. Neurosci Res, 2002,43:75
6Tanahashi N, Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern Med, 2002, 41:337
